ArticleJournal of biomaterials science. Polymer edition2021
Polymer-based nano-therapies to combat COVID-19 related respiratory injury: progress, prospects, and challenges.
Article in Journal of biomaterials science. Polymer edition, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 38 citations in OpenAlex.
- Nanotechnology in COVID-19 prevention, diagnosis, and treatment: a comprehensive review.Discover nano · 2025Review
- Nitric Oxide in the Treatment of COVID-19: Nasal Sprays, Inhalants and Nanoparticles.Biochemistry research international · 2025Review
- Article
- Nonviral nanoparticle gene delivery into the CNS for neurological disorders and brain cancer applications.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023Review
- Polymeric Materials as Indispensable Tools to Fight RNA Viruses: SARS-CoV-2 and Influenza A.Bioengineering (Basel, Switzerland) · 2022Review
- Polymeric nanoparticles as therapeutic agents against coronavirus disease.Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology · 2022Review
- Polymeric Materials as Potential Inhibitors Against SARS-CoV-2.Journal of polymers and the environment · 2022Review
- Pharmacologic therapies of ARDS: From natural herb to nanomedicine.Frontiers in pharmacology · 2022Review
- The Potential Contribution of Biopolymeric Particles in Lung Tissue Regeneration of COVID-19 Patients.Polymers · 2021Review
- Unleashing the potential of cell membrane-based nanoparticles for COVID-19 treatment and vaccination.Expert opinion on drug delivery · 2021Article
- Polyester Polymeric Nanoparticles as Platforms in the Development of Novel Nanomedicines for Cancer Treatment.Cancers · 2021Review
- Advances and Perspectives in the Use of Carbon Nanotubes in Vaccine Development.International journal of nanomedicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent coronavirus disease-2019 (COVID-19) outbreak has increased at an alarming rate, representing a substantial cause of mortality worldwide. Respiratory injuries are major COVID-19 related complications, leading to poor lung circulation, tissue scarring, and airway obstruction. Despite an in-depth investigation of respiratory injury's molecular pathogenesis, effective treatments have yet to be developed. Moreover, early detection of viral infection is required to halt the disease-related long-term complications, including respiratory injuries. The currently employed detection technique (quantitative real-time polymerase chain reaction or qRT-PCR) failed to meet this need at some point because it is costly, time-consuming, and requires higher expertise and technical skills. Polymer-based nanobiosensing techniques can be employed to overcome these limitations. Polymeric nanomaterials have the potential for clinical applications due to their versatile features like low cytotoxicity, biodegradability, bioavailability, biocompatibility, and specific delivery at the targeted site of action. In recent years, innovative polymeric nanomedicine approaches have been developed to deliver therapeutic agents and support tissue growth for the inflamed organs, including the lung. This review highlights the most recent advances of polymer-based nanomedicine approaches in infectious disease diagnosis and treatments. This paper also focuses on the potential of novel nanomedicine techniques that may prove to be therapeutically efficient in fighting against COVID-19 related respiratory injuries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.